Publication: Antimalarial drug resistance: a threat to malaria elimination
Issued Date
2017-07-01
Resource Type
ISSN
21571422
Other identifier(s)
2-s2.0-85022327249
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cold Spring Harbor Perspectives in Medicine. Vol.7, No.7 (2017), 1-24
Suggested Citation
Didier Menard, Arjen Dondorp Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harbor Perspectives in Medicine. Vol.7, No.7 (2017), 1-24. doi:10.1101/cshperspect.a025619 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/41857
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Antimalarial drug resistance: a threat to malaria elimination
Author(s)
Other Contributor(s)
Abstract
© 2017 Cold Spring Harbor Laboratory Press; all rights reserved. Increasing antimalarial drug resistance once again threatens effective antimalarial drug treatment, malaria control, and elimination. Artemisinin combination therapies (ACTs) are first-line treatment for uncomplicated falciparum malaria in all endemic countries, yet partial resistance to artemisinins has emerged in the Greater Mekong Subregion. Concomitant emergence of partner drug resistance is now causing high ACT treatment failure rates in several areas. Genetic markers for artemisinin resistance and several of the partner drugs have been established, greatly facilitating surveillance. Single point mutations in the gene coding for the Kelch propeller domain of the K13 protein strongly correlate with artemisinin resistance. Novel regimens and strategies using existing antimalarial drugs will be needed until novel compounds can be deployed. Elimination of artemisinin resistance will imply elimination of all falciparum malaria from the same areas. In vivax malaria, chloroquine resistance is an increasing problem.